The Filing Desk

Crescent Biopharma

CBIO · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CBIO · Last close · November 19, 2026
$12.91
Value Crescent Biopharma yourself

Crescent Biopharma reported revenue of $11 million in fiscal 2025. Its operating margin was −1,407.5%. Free cash flow was −$72 million.

Crescent Biopharma, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-011983 Updated
Revenue
$11M
 
Operating margin
−1,407.5%
 
Net income
−$154M
 
Free cash flow
−$72M
 
Return on equity
−164.2%
166.1 pts
Market cap
$833M
Nov 19 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Crescent Biopharma does

Crescent Biopharma is a clinical-stage cancer drug company, so it has no approved products. It was formerly GlycoMimetics and took its current form in a June 2025 merger with a private company, also named Crescent Biopharma. It moved its legal home to the Cayman Islands in the same transaction.

It has two strategies. One is CR-001, an antibody designed to bind two targets at once, PD-1 and VEGF, which it hopes could take the place of Merck's Keytruda as a base cancer treatment. The other is a group of antibody drug conjugates, which carry a cancer-killing drug straight to tumor cells. These include CR-002 and CR-003. It plans to combine them in treatment.

It started a global Phase 1/2 trial of CR-001, called ASCEND, in February 2026. It expects to start trials for CR-002 and CR-003 on their own in 2026, plus the first combination trial with CR-001. It has never earned revenue from product sales.

Its biggest risks, as it describes them

  • It has never had product revenue and may never be profitable.
  • It needs more money, and raising it may dilute shareholders or require giving up rights.
  • It depends on its lead programs CR-001, CR-002 and CR-003, which may not succeed.
  • Its approach to finding and developing drugs is unproven, and others may compete in the same diseases.
From Crescent Biopharma's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Crescent Biopharma lost money in fiscal 2025: a net loss of $154 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments90484235213
Debt incl. finance leases———380
Net debt (negative means net cash)———3−213
Net debt to EBITDA—————
Debt to equity————0.0x
Interest coverage————−69.8x
Current ratio7.7x5.7x6.4x3.6x6.6x
Quick ratio7.7x5.7x6.4x3.6x6.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Crescent Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $30.6 million of Crescent Biopharma shares on the open market, and 7 insiders sold $1.5 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 18, 2026Joshua T BrummChief Executive Officer, DirectorSold plan7,837$16.71$130,956Form 4
Sep 18, 2026Jonathan McNeillPresident and COOSold plan3,839$16.71$64,150Form 4
Sep 16, 2026Joshua T BrummChief Executive Officer, DirectorSold plan1,610$17.90$28,819Form 4
Sep 16, 2026Jonathan McNeillPresident and COOSold plan731$17.90$13,085Form 4
Sep 16, 2026Jan PinkasChief Scientific OfficerSold plan658$17.90$11,778Form 4
Sep 16, 2026Ellie Eunkyung ImChief Medical OfficerSold plan623$17.90$11,152Form 4
Sep 16, 2026Barbara Harlin BisphamSee RemarksSold plan620$17.90$11,098Form 4
Sep 16, 2026Richard William ScalzoChief Financial OfficerSold plan568$17.90$10,167Form 4
Sep 16, 2026Ryan LynchSee RemarksSold plan240$17.90$4,296Form 4
Jul 16, 2026Fairmount Healthcare Fund II L.P.Director, 10% ownerBought853,450$14.50$12.4 millionForm 4
Jun 22, 2026Joshua T BrummChief Executive Officer, DirectorSold plan42,305$17.99$761,067Form 4
Jun 22, 2026Jonathan McNeillPresident and COOSold plan20,549$17.99$369,677Form 4
The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−349,099.6%——
Altman Z''−27.47−4.904.59
Accruals ratio−4.2%−16.8%−59.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets——Pass
Current ratio rosePassFailPass
Share count didn't riseFailFail—
Gross margin rose———
Revenue rose relative to assetsFail——
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Crescent Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Crescent BiopharmaFY25—−1,407.5%−668.1%———
Zenas BioPharmaFY25100.0%−3,830.6%−1,723.5%———Compare
PrecigenFY25146.7%−1,141.1%−927.6%——2Compare
Prelude TherapeuticsFY2573.4%−861.3%−464.3%———Compare
EvommuneFY2585.7%−623.6%−589.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0———10100—11
Revenue growth−99.9%————−88.6%−93.5%−86.7%——
Gross profit——————————
Research and development232440474548282014138
Operating income−32−34−52−61−52−63−47−39−40−153
Net income−32−33−48−58−51−63−47−37−38−154
Diluted EPS (US$)−1.50−1.13−1.18−1.34−1.12−1.23−0.89−0.58−0.59—
Diluted shares (millions)212941434652526364—
Cash flow
Cash from operations−30−30−43−52−39−58−46−35−31−72
Capital expenditure1000000001
Free cash flow−30−30−43−52−39−58−47−35−31−72
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation34567644513
Balance sheet at fiscal year end
Cash and short-term investments4012421015813790484235213
Debt incl. finance leases————————380
Total assets4212921516814394524536240
Total liabilities799141513974737
Shareholders' equity35120206154128824338−16203
Margins and ratios
Gross margin——————————
Operating margin−172,505.3%———−506.8%−5,470.7%−63,204.4%−392,752.9%—−1,407.5%
Net margin−171,945.1%———−502.1%−5,469.0%−62,251.7%−368,994.2%—−1,419.6%
Free cash flow margin−164,516.0%———−386.8%−4,958.3%−62,055.6%−349,013.0%—−668.1%
Rule of 40 (growth + FCF margin)−164,616.0%————−5,046.9%−62,149.1%−349,099.6%——
Return on capital——————————
Return on equity−84.0%−42.9%−29.7%−32.2%−36.1%−60.5%−75.0%−90.7%−330.3%−164.2%
Return on assets−70.0%−38.9%−28.1%−30.2%−32.8%−53.5%−63.9%−76.0%−93.6%−111.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Crescent Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Crescent Biopharma.